In blood spiking experiments with carcinoma cells that have high levels of EpCAM, the sensitivity to detect CTCs is higher than 85% [94,95], but with cells that express low levels of EpCAM, the sensitivity is about 42% [96]. This evidence concerns the gene EPCAM and carcinoma.